Remove Biosimilars Remove Pharmaceuticals Remove Trials
article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. Understanding the Pharmaceutical Market Dynamics The pharmaceutical industry is a complex ecosystem where branded drugs and generics coexist, each playing a vital role in patient care and market dynamics.

article thumbnail

Regulatory considerations for biosimilar clinical efficacy trials

Drug Patent Watch

Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the fight against high healthcare costs. Another critical consideration is the choice of comparator arm.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Building the requisite clinical development infrastructure for medical innovation to thrive

Drug Target Review

When these trials fail, the repercussions can be devastating, leading to layoffs and a significant loss of morale among remaining team members. Boasting more than two decades of experience in pharmaceutical, biotechnology and contract research organisations (CROs), Vishal possesses deep insights into research and drug development strategies.

article thumbnail

Educating Patients about Generic Drugs: Strategies for Success

Drug Patent Watch

Generic drugs are pharmaceutical products that contain the same active ingredients as their brand-name counterparts. Trial Periods Offer patients a trial period with the generic drug, assuring them that they can switch back to the brand-name medication if they experience any issues. What Are Generic Drugs? ” FDA.gov, 2021.

Drugs 69
article thumbnail

The Competitive Edge of Biosimilars

DrugBank

Biosimilars  Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.

article thumbnail

Analyzing the impact of biosimilars on biologic drug manufacturing technologies

Drug Patent Watch

Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies.

article thumbnail

Trends in Pharmaceutical Mergers and Acquisitions

DrugBank

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.